Cloud DX Announces Voluntary Extension of Lock-up Agreements with Company Insiders Medical Device Investing
U.S. FDA Approves Pfizer's CIBINQO® for Adults with Moderate-to-Severe Atopic Dermatitis Pharmaceutical Investing
U.S. FDA Approves RINVOQ® to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis Pharmaceutical Investing
Medtronic announces results showing meaningful pain relief using DTM Spinal Cord Stimulation endurance therapy Medical Device Investing
Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product Pharmaceutical Investing
UNIVERSAL IBOGAINE ANNOUNCES WORLD-CLASS CLINICAL TRIAL PARTNERS IN ADVANCE OF CLINICAL TRIAL APPLICATION FOR IBOGAINE IN OPIOID USE DISORDER Pharmaceutical Investing
Numinus Announces Cancellation and Rescheduling of Annual General Meeting of Shareholders Pharmaceutical Investing
Naturally Splendid Closes Second Tranche of $1,120,456 for a Total Raise of $3,270,971 Life Science Investing
Bausch + Lomb Corporation Files Registration Statement and Preliminary Prospectus for Proposed Initial Public Offering Pharmaceutical Investing
NeonMind Appoints Canadian Medical Leader in Anesthesiology, Dr. Daniel Bainbridge, MD, FRCPC to Its Specialty Clinics Advisory Board Psychedelics Investing
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
